SCHEMBL4532235

SCHEMBL4532235

CCOC(=O)c1sc2nc(CC3=CCCCC3)nc(Cl)c2c1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.61
KDM4E B2RXH2 7/20 0.61
NPSR1 Q6W5P4 5/20 0.47
HPGD P15428 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 3/20 0.47
STAT3 P40763 1/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 6/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
RXFP1 Q9HBX9 2/20 0.46
KCNH2 Q12809 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.44
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520288 0.79 KMT2A (0.57) ALDH1A1KDM4ENPSR1HPGDLMNA
SCHEMBL4510412 0.78 KMT2A (0.66) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2
SCHEMBL4531480 0.78 ALDH1A1 (0.61) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2
SCHEMBL4512178 0.77 KDM4E (0.58) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2
SCHEMBL4521870 0.76 KMT2A (0.58) ALDH1A1KDM4ENPSR1HPGDLMNA
SCHEMBL4531402 0.75 KDM4E (0.58) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2
SCHEMBL4506050 0.75 ALDH1A1 (0.58) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2
SCHEMBL4524904 0.75 KDM4E (0.55) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2
SCHEMBL4510264 0.74 ALDH1A1 (0.57) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2
SCHEMBL4514789 0.73 ALDH1A1 (0.55) ALDH1A1KDM4ENPSR1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 ALDH1A1 2303/4885KDM4E 2859/4885NPSR1 476/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 ALDH1A1 2303/4885KDM4E 2859/4885NPSR1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.